Journals / The European Research Journal / 2016 / Cilt: 2 - Sayı: 3

Transapical transcatheter aortic valve implantation in a high-risk patient with aortic and mitral regurgitation: usage of the JenaValve™ system

Pages
219–221
Publication Date
2016-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We performed a transapical transcatheter aortic valve implantation procedure using this system without any procedure-related complications in a 75-year-old woman with multiple co-morbidity factors, who had both mitral and aortic regurgitation, and low ejection fraction.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:JenaValveTM system is a second-generation transcatheter heart valve that provides a successful deployment not only in calcified stenotic aortic valves but also in non-calcified, severe regurgitant aortic valves.
📊
Key Findings & Data:JenaValveTM system is a second-generation transcatheter heart valve that provides a successful deployment not only in calcified stenotic aortic valves but also in non-calcified, severe regurgitant aortic valves.
💡
Conclusion & Impact:We performed a transapical transcatheter aortic valve implantation procedure using this system without any procedure-related complications in a 75-year-old woman with multiple co-morbidity factors, who had both mitral and aortic regurgitation, and low ejection fraction.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Aortic regurgitation · mitral regurgitation · transcatheter aortic valve implantation

Abstract

JenaValveTM system is a second-generation transcatheter heart valve that provides a successful deployment not only in calcified stenotic aortic valves but also in non-calcified, severe regurgitant aortic valves. We performed a transapical transcatheter aortic valve implantation procedure using this system without any procedure-related complications in a 75-year-old woman with multiple co-morbidity factors, who had both mitral and aortic regurgitation, and low ejection fraction.

🔖

Cite This Article

SURER, S., INCE, İ., DUVAN, İ., BAYYURT, C., KİZİLTEPE, U. (2016). Transapical transcatheter aortic valve implantation in a high-risk patient with aortic and mitral regurgitation: usage of the JenaValve™ system. The European Research Journal, Cilt: 2 - Sayı: 3, 219–221. https://ajindex.com/articles/704020

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-96.
  2. Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, et al. 2012 ACCF/ AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012;59:1200-54.
  3. Seiffert M, Bader R, Kappert U, Rastan A, Krapf S, Bleiziffer S, et al. Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv 2014;7:1168-74.